2011
DOI: 10.1002/cbic.201100162
|View full text |Cite
|
Sign up to set email alerts
|

Osteocalcin Biomimic Recognizes Bone Hydroxyapatite

Abstract: Twinkle, twinkle little bone! A short peptide derived from a natural bone binding protein, osteocalcin, shows excellent selectivity and affinity to hydroxyapatite, the main component of bone. With a fluorescent label, the intravenously injected peptide revealed detailed bone structures in mice, like an X‐ray image (see figure).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
12
0

Year Published

2012
2012
2018
2018

Publication Types

Select...
6

Relationship

4
2

Authors

Journals

citations
Cited by 11 publications
(13 citation statements)
references
References 24 publications
(37 reference statements)
1
12
0
Order By: Relevance
“…Its Gla residues enable the peptide to bind to CHA but not to other calcium compounds such as calcium oxalate, calcium carbonate, or calcium pyrophosphate. In this study we have used a fluorescein-conjugated peptide (FITC-HABP-19) to visualize CHA in CVC cultures and to monitor calcification in them [6]. …”
Section: Introductionmentioning
confidence: 99%
“…Its Gla residues enable the peptide to bind to CHA but not to other calcium compounds such as calcium oxalate, calcium carbonate, or calcium pyrophosphate. In this study we have used a fluorescein-conjugated peptide (FITC-HABP-19) to visualize CHA in CVC cultures and to monitor calcification in them [6]. …”
Section: Introductionmentioning
confidence: 99%
“…FITC-labeled HABP-19 and the corresponding FITC-labeled control cHABP probes were prepared as previously described [27]. The sequences of HABP-19 and control cHABP are FITC-βAγEPRRγEVAγELγEPRRγEVAγEL-NH 2 and FITC-βAEPRREVAELEPRREVAEL-NH 2 , respectively.…”
Section: Methodsmentioning
confidence: 99%
“…However, HA calcifications can be found in both benign and malignant lesions, although they are most often seen in proliferative lesions, including carcinoma [2426]. Recently, we have developed a HA binding peptide (HABP-19) inspired from protein OCN that was used as a targeting imaging contrast for HA calcification in cardiovascular diseases and early osteoblastic activity [23,27]. In the present work we have used HABP-19 molecular imaging agent to validate HA calcification in osteotropic tumors (ex vivo) and human SaOS-2 cells (in vitro).…”
Section: Introductionmentioning
confidence: 99%
“…15 Previously a 19-mer peptide, called HABP-19, that incorporated six residues of Gla was developed by us and showed excellent properties as a bone imaging probe both in vitro and in vivo. 9 In that study, it was found that the peptide lost its affinity to HA if the unusual bidentate Gla residues were replaced by normal Glutamate (Glu) residues (Figure 1), which have only one carboxyl group on the side chain, suggesting the critical role of the bidentate structure. An iminodiacetate (IDA) group (Figure 1), which imitates the bidentate structure of dicarboxylate group on the Gla side chain, has been explored for bone binding.…”
mentioning
confidence: 94%